Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Cash from Investing Activities (2022 - 2025)

Envoy Medical's Cash from Investing Activities history spans 4 years, with the latest figure at -$1000.0 for Q2 2025.

  • For Q2 2025, Cash from Investing Activities rose 99.87% year-over-year to -$1000.0; the TTM value through Sep 2025 reached $527000.0, up 134.33%, while the annual FY2024 figure was -$980000.0, 540.52% down from the prior year.
  • Cash from Investing Activities for Q2 2025 was -$1000.0 at Envoy Medical, up from -$6000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $534000.0 in Q4 2024 and bottomed at -$790000.0 in Q2 2024.
  • The 4-year median for Cash from Investing Activities is -$41000.0 (2022), against an average of -$107363.6.
  • The largest YoY upside for Cash from Investing Activities was 2642.86% in 2024 against a maximum downside of 7081.82% in 2024.
  • A 4-year view of Cash from Investing Activities shows it stood at -$41000.0 in 2022, then soared by 48.78% to -$21000.0 in 2023, then skyrocketed by 2642.86% to $534000.0 in 2024, then plummeted by 100.19% to -$1000.0 in 2025.
  • Per Business Quant, the three most recent readings for COCH's Cash from Investing Activities are -$1000.0 (Q2 2025), -$6000.0 (Q1 2025), and $534000.0 (Q4 2024).